US Stock MarketDetailed Quotes

ALT Altimmune

Watchlist
  • 9.030
  • +0.440+5.12%
Close Dec 13 16:00 ET
  • 8.920
  • -0.110-1.22%
Post 19:52 ET
642.26MMarket Cap-5.75P/E (TTM)

Altimmune Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Altimmune Q3 2024 Earnings Date

Currency：USDNov 12, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
620.00
5.00K
+4.38K
Beat Est.
-99.83%
-98.62%
+706.45%
EPS
-0.36
-0.32
+0.04
Beat Est.
+7.95%
+17.95%
+10.84%
Analyst Rating
Strong Buy

Dec 3, 2024

Altimmune Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
Date Period Revenue/Estimate Earnings Call
-- 2025/Q1 -- / 1.000K --
-- 2024/Q4 -- / 0.000 --
Nov 12, 2024 2024/Q3 5.000K / 620.000 --
Aug 8, 2024 2024/Q2 5.000K / 620.000 --
May 9, 2024 2024/Q1 5.000K / 0.000 --
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 1.000K--
--2024/Q4-- / 0.000--
Nov 12, 20242024/Q35.000K / 620.000--
Aug 8, 20242024/Q25.000K / 620.000--
May 9, 20242024/Q15.000K / 0.000--

Unlock Free Earnings Estimates

Altimmune Earnings Reports

  • Altimmune | 10-Q: Q3 2024 Earnings Report

    Nov 13 05:13

  • Altimmune | 8-K: Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

    Nov 13 01:35

  • Altimmune | 10-Q: Q2 2024 Earnings Report

    Aug 9 04:10

  • Altimmune | 8-K: Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

    Aug 8 19:09

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 3, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data

    Investment Theme Weight Loss Drugs
    Weight Loss Drugs
    Intraday-0.11%